The opportunity appears to be related to antimicrobial resistance AI, which aligns with the venture's focus on predicting drug resistance mutations. However, the provided information is limited and does not clearly indicate a funding opportunity or a specific program. The venture's goals and technology may be relevant to this opportunity, but more information is needed to determine a strong fit.